I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

SOHO 2024

-
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features

Sep 4 / Roche and Genentech
Real-World Comparative Outcomes of First-Line (1L) Venetoclax + Obinutuzumab▼ (VenO) versus Bruton's Tyrosine Kinase Inhibitors (BTKis) Anti-CD20 Therapy Among Patients with Chronic Lymphocytic Leukemia (CLL) in the United States (US)
A retrospective cohort study of patients with chronic lymphocytic leukemia (CLL) in the United States, using data obtained from the Flatiron Health database, was conducted. Comparative outcomes, including time to next treatment or death and time to next alternative regimen, were assessed in patients receiving first-line venetoclax-obinutuzumab▼ and Bruton’s tyrosine kinase inhibitors (ibrutinib or acalabrutinib), with and without anti-CD20 therapy.

Sign up or login to unlock the full suite of MEDICALLY features

Sep 4 / Roche and Genentech
Real-World Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia Receiving First-Line Treatment with Venetoclax + Obinutuzumab▼ versus Bruton's Tyrosine Kinase Inhibitors
A retrospective cohort study of patients with chronic lymphocytic leukemia (CLL) in the United States, using data obtained from the IQVIA PharMetrics® Plus database, was conducted. Healthcare costs associated with first-line venetoclax-obinutuzumab▼ and Bruton’s tyrosine kinase inhibitors (ibrutinib or acalabrunitinb) for the treatment of CLL are presented in this poster.
01:15 PM
Duration 45mins Houston, Texas
Real-World Comparative Outcomes of First-Line (1L) Venetoclax + Obinutuzumab▼ (VenO) versus Bruton's Tyrosine Kinase Inhibitors (BTKis) Anti-CD20 Therapy Among Patients with Chronic Lymphocytic Leukemia (CLL) in the United States (US)
Li S, Ravelo A, Schuldt R, Shahkarami M, Thompson MC

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 45mins Houston, Texas
Real-World Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia Receiving First-Line Treatment with Venetoclax + Obinutuzumab▼ versus Bruton's Tyrosine Kinase Inhibitors
Ravelo A, Patel A, To TM, Li SS, Huntington S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar